Listen: Moderna’s setback, the saga of drug pricing reform & a CEO’s next act

Is drug pricing reform actually happening? Why was Moderna’s stock down? And what’s next for Alnylam’s CEO?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. STAT’s Rachel Cohrs drops in to talk about the latest updates in drug pricing reform. Then, John Maraganore joins us to talk about his decision to step down as CEO of Alnylam Pharmaceuticals after almost 20 years with the company. We also discuss the latest news in biotech, including the Covid-19 vaccine for kids and Moderna’s disappointing earnings call.

For more on what we cover, here’s the story on the CDC endorsing Pfizer’s Covid-19 vaccines for kids; here’s the news from Alnylam; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.

Be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].